Gregg W. Stone, MD

Country USA
Specialty Interventional Cardiologist
  1. How to Treat: Left Main & 3 Vessel Disease
  2. Left Main Revascularization: Data Supports PCI in Most Cases
  3. Which Patients with Stable CAD Benefit from PCI in the Post-ISCHEMIA Era?
  4. Left Main PCI vs. CABG: Form the Final EXCEL Outcomes to Patient Recommendations
  5. Transcatheter Mitral Valve Repair: Guideline Changes, Evidence Gaps and Future Directions
  6. New Insights from the COAPT: Patient Eligibility and Timing
  7. EXCEL Trial: Extended Long-term and Key Clinical Substudies
  8. Mitral Valve: Future Perspectives
  9. Long-term and Updated Data from EXCEL and NOBLE
  10. ONYX One and ONYX One CLEAR Trials of 1-month DAPT After Onyx
  11. The COAPT Trial: How the Trial Succeed?
  12. Deep Dive into Mitraclip Trials for Functional MR
  13. Long-term Outcomes and More Data from ABSORB Trials
  14. FFRCT to Guide Revascularization Decisions: The DECISION Trial
  15. COAPT
  16. Inter-Atrial Shunts in HF: Devices, Indication, and Outcomes
  17. Future Perspectives of BRS, Will It Go Forward or Not?
  18. XIENCE Safety ; Review of XIENCE DAPT Clinical Evidence and Clinical Program
  19. ABSORB IV: 30-day Outcomes from a Randomized Trial of a Bioresorbable Scaffold Versus a Metallic DES in Patients with Coronary Artery Disease
  20. ABSORB III, IV, Updated Meta, and More - Expert Future Expectation on Bioabsorbable Scaffolds
  21. Clinical Trials in Functional Mitral Regurgitation
  22. [Satellite Lecture] PCI Outcomes with Bioresorbable Scaffolds: Role of Technique and DAPT
  23. [Satellite Lecture]Congratulatory Remark & Keynote Lecture: “Left Main Intervention Comes of Age: A 40-Year Odyssey from Balloon Angioplasty to Drug-Eluting Stents”
  24. The Future PROSPECT for the Role of Antiplatelet Therapy
  25. Why Do We Need a Fully Bioresorbable Vascular Scaffold; From Absorb III and ABSORB Meta-Analysis to the Future
  26. ABSORB III - Current and Future Use of Bioresorbable Scaffolds
  27. Drug-Eluting Stents vs. Bioresorbable Vascular Scaffolds: Is Newer Better?  
  28. Management of Stable Coronary Heart Disease with Objective Ischemia: COURAGE, FAME2 and Recent Meta-Analysis
  29. BRS: From ABSORB III to the Future
  30. Left Main PCI: Anticipating EXCEL
  31. PLATO: Impact on the Management of ACS and Personalizing Treatment with Ticagrelor
  32. Evolution, BVS Unique Benefits, Clinical Perspectives on Angina
  33. UFH Versus Bivalirudin: Which One Should I Use?
  34. Focal Treatment of Vulnerable Plaque: Stents, Scaffolds and Prospect II
  35. Future Roadmap of the Mitral Valve Therapies
  36. Vulnerable Plaque Detection and Treatment: PROSPECT II and PROSPECT ABSORB
  37. Bioresorbable Scaffolds in a "Nutshell": Updates and Expectations
  38. Lessons from the Pooled Data using Xience Everolimus-eluting Stent
  39. Evidence-based Pharmacotherapy for ACS Patients: The Forest and the Trees
  40. Reduction of Thrombus: Routine vs. Selective Aspiration
  41. Current Status of EXCEL Study
  42. New Insights Regarding the Safety and Efficacy of DAPT After Stenting
  43. Latest Update of PLATINUM Trial: Promus Element Workhorse Two Year Follow-up
  44. PCI Today: Best Practices, Optimal Outcomes, and Limitations: When Do I Prefer CABG for MVD?
  45. What’s Known and Unknown about LM PCI: Transitioning from SYNTAX to EXCEL
  46. PLATINUM Workhorse Data from ACC
  47. Xience Platform Safey Update
  48. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV)
  49. The EXCEL Trial
  50. DES in Left Main Disease: New Guidelines and Updates from EXCEL
  51. Motivation, Objective and Implication of EXCEL Study
  52. Bioabsorble or Free-Polymer DES: Current and New Technologies
  53. Milestone for Left Main PCI: Upcoming Excel LM Trial
  54. Does PROSPECT Support the Use of Invasive Imaging to Diagnose and Treat Vulnerable Plaque with DES?
  55. Introducing EXCEL: The \"Definitive\" Unprotected Left Main Randomized Trial!
  56. The Latest Updates in DES Clinical Data
  57. STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel)
  58. Linkage of Current Plaque Vulnerability to Future Events: Evidence from PROSPECT Study
  59. HORIZONS AMI: A Large Prospective Randomized Trial of PES vs. BMS in Patients with STEMI
  60. Comparison of DES versus BMS in Real World Registries
  61. New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us?
  62. Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS
  63. HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use
  64. HORIZONS AMI AMI: Prospective Randomized Trials of Paclitaxel-Eluting Stents vs. BMS in Patients with STEMI
  65. COOL RCN : Randomized Trail of Systemic Hypothermia for Prevention of Radiocontrast Nephropathy
  66. Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible
  67. SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent)
  68. Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data
  69. SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease
  70. ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results
  71. The Baseline Clinical Features and Plaque Characteristics from the PROSPECT Trial
  72. Should DES Use be Reduced Due to Safety Concerns? Important Messages from the Randomized DES Trials
  73. 2007 Guidelines Update for DES: An Evidence-Based Medicine Critical Analysis
  74. Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians
  75. Taxus V Clinical Update
  76. Optimizing Outcomes of Primary PCI: From CADILLAC to HORIZONS
  77. EMERALD Trial: Lessons Learned
  78. Zen Philosophy - The KEY to CTO Success
  79. Evidence-Based Medicine Analysis of Current DES Clinical
  80. Recent Updates from the Taxus Trials (Taxus 2 and 4 Late FU, Taxus Meta-Analysis, and Taxus 5)
  81. Paclitaxel-Eluting TAXUS Stents Strengths and Weaknesses